NewsEvents

Your Yourlocation: Home > Evaluation of the efficacy of combined tiotropium bromide(136310-93-5) and budesonide dermoterol in moderate to severe stable chronic obstructive pulmonary disease

OBJECTIVE: To evaluate the efficacy of combined inhalation of tiotropium bromide(136310-93-5) and budesonide dermotero in patients with moderate to severe chronic obstructive pulmonary disease(COPD).

METHODS: Seventy-two patients with moderate to severe COPD were divided into two groups according to the random number table method: (1) 37 patients in the treatment group, inhaled budesonide dermotril 160 /4.5 μg twice daily for 2 times; (2) 35 cases in the control group, inhaled budesonide dermotam 160 /4.5 μg, 2 times a day 2 times to observe the patients before treatment, 4,16,24 W exercise tolerance, dyspnea score, changes in lung function.

RESULTS: After 6 min, 6 (6MWD), FEV1 and FVC were significantly increased in the two groups after treatment at 4, 16 and 24 W, the dyspnea score (MMRC) and RV were significantly lower than those before treatment (P <0.05). The improvement of the indexes in the treatment group was significantly better than that in the control group(P <0.05).

Conclusion: Tiotropium bromide(136310-93-5) combined with budesonide dermotam compound in the treatment of moderate to severe stable COPD is better than inhaled budesonide dermotam treatment.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved